Bond Johnson & Johnson Inc. 4.85% ( US478160BA19 ) in USD
Issuer | Johnson & Johnson Inc. | ||
Market price | ![]() |
||
Country | ![]() |
||
ISIN code |
![]() |
||
Interest rate | 4.85% per year ( payment 2 times a year) | ||
Maturity | 15/05/2041 | ||
|
|||
Minimal amount | 2 000 USD | ||
Total amount | 300 000 000 USD | ||
Cusip | 478160BA1 | ||
Standard & Poor's ( S&P ) rating | AAA ( Prime - Investment-grade ) | ||
Moody's rating | Aaa ( Prime - Investment-grade ) | ||
Next Coupon | 15/11/2025 ( In 60 days ) | ||
Detailed description |
Johnson & Johnson is a multinational corporation that manufactures and sells a wide range of healthcare products, including pharmaceuticals, medical devices, and consumer packaged goods. This financial article presents a detailed overview of a highly-rated corporate bond issued by Johnson & Johnson, a global leader in healthcare headquartered in the United States, renowned for its diverse portfolio spanning pharmaceuticals, medical devices, and consumer health products, underpinning its robust financial standing. The bond, identified by ISIN US478160BA19 and CUSIP 478160BA1, is a USD-denominated obligation currently trading at its par value of 100%. Investors in this instrument are offered an annual interest rate of 4.85%, with payments distributed semi-annually, reflecting its frequency of payment of two per year. The total size of this particular issue amounts to 300,000,000 USD, with a minimum acquisition threshold set at 2,000 USD. Demonstrating exceptional credit quality, the bond carries the highest possible ratings from leading agencies: 'AAA' from Standard & Poor's (S&P) and 'Aaa' from Moody's, signifying an extremely low credit risk profile. Its long-term nature is highlighted by a maturity date of May 15, 2041, making it a compelling consideration for investors seeking stable, high-quality fixed-income exposure over an extended horizon. |